Zoetis Inc. $ZTS Stock Acquired by Profund Advisors LLC

Profund Advisors LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 226.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,433 shares of the company’s stock after purchasing an additional 17,649 shares during the period. Profund Advisors LLC’s holdings in Zoetis were worth $1,776,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. ProShare Advisors LLC boosted its stake in Zoetis by 5.6% in the third quarter. ProShare Advisors LLC now owns 115,215 shares of the company’s stock worth $8,045,000 after buying an additional 6,119 shares in the last quarter. Vise Technologies Inc. lifted its stake in Zoetis by 52.9% in the third quarter. Vise Technologies Inc. now owns 14,886 shares of the company’s stock worth $1,039,000 after purchasing an additional 5,151 shares during the last quarter. Cidel Asset Management Inc. boosted its position in Zoetis by 17.5% during the third quarter. Cidel Asset Management Inc. now owns 4,003 shares of the company’s stock valued at $280,000 after buying an additional 595 shares during the period. State of Wyoming boosted its position in Zoetis by 120.9% during the third quarter. State of Wyoming now owns 4,540 shares of the company’s stock valued at $317,000 after buying an additional 2,485 shares during the period. Finally, International Assets Investment Management LLC boosted its position in Zoetis by 204.8% during the third quarter. International Assets Investment Management LLC now owns 20,000 shares of the company’s stock valued at $1,397,000 after buying an additional 13,439 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. UBS Group lifted their price objective on Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Tuesday, October 27th. Piper Sandler lowered their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Citigroup dropped their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Jefferies Financial Group lowered Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the stock from $103.00 to $83.00 in a research report on Tuesday, October 20th. Finally, HSBC reduced their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Six analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $93.79.

Zoetis Price Performance

Shares of Zoetis stock opened at $83.18 on Tuesday. The business has a 50 day moving average of $75.15 and a 200 day moving average of $93.43. Zoetis Inc. has a 52 week low of $68.77 and a 52 week high of $144.83. The company has a market cap of $34.37 billion, a PE ratio of 11.82, a P/E/G ratio of 1.15 and a beta of 0.74. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period in the prior year, the business earned $1.76 EPS. The company’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.15 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s payout ratio is presently 34.93%.

Zoetis Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.